Sign in
TerminatedNo phase

Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

Key facts

Who runs it
UNC Lineberger Comprehensive Cancer Center
Where
Chapel Hill, United StatesSee the site
Trial code
Status
Terminated
People taking part
10 people enrolled
Started
28 May 2021
Ended
25 May 2024
Type of study
Observational
Record updated
5 July 2024
Why it stopped
Resources related issues

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Adult patients (≥18 years of age) diagnosed with AML who are going to undergo stem cell transplant (SCT). These subjects must provide written informed consent to participate
  • Subjects must have an identified mutation that has been validated on the multiplex daPCR assay

Who cannot take part

  • Adult patients (≥18 years of age) diagnosed with AML who are scheduled to undergo SCT at the NCCH who do not provide written informed consent to participate are ineligible

Where in United States

  • North Carolina Cancer Hospital (NCCH)Chapel Hill, United States

About the trial

What the trial wants to find out

Purpose: The purpose of this trial is to investigate whether a digital array assay can detect trace amounts of residual leukemia and predict relapse in acute myeloid leukemia (AML) patients in remission who have undergone allogeneic stem cell transplantation (SCT) at the North Carolina Cancer Hospital (NCCH).

Read full original descriptionShow less

Participants: Adult patients (18 years of age or older) with diagnosed AML who are going to undergo stem cell transplant (SCT).

Procedures (methods): A total of 10 eligible subjects will be treated per standard of care with SCT. Peripheral blood and bone marrow aspirate (10 mL each) for digital array assay analysis will be collected along with routine lab draws and bone marrow biopsy procedures prior to SCT. Beginning 1 month after SCT peripheral blood (10 ml) will be collected to assess MRD by digital array assay analysis on a monthly basis for up to 6 months. In addition, bone marrow aspirate will be collected at approximately Month 3 and 6 following SCT for assay analysis. Patient medical records will be reviewed 6 and 12 months after completing their last MRD follow up assessment to confirm survival status, remission status, and gather information related to relapse.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
LCCC 2103: Development and Application of a Novel Digital Array PCR Assay for Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia (AML)
Record updated
5 July 2024